Alibaba Unveils China's Most Powerful AI Chip; On Holding Eyes High-Teens Sales Growth

Roche reported encouraging top-line results from a mid-stage study of enicepatide, its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes and overweight or obesity. In the 447-patient phase II CT-388-104 study, enicepatide met both primary endpoints at 48 weeks, delivering dose-dependent reductions in HbA1c and body weight. At the highest titrated dose of 24 mg, enicepatide reduced HbA1c by 2.65% from a baseline of 8.1%, with about 90% of patients achieving an HbA1c of 6.5% or lower and 62% reaching normoglycemia below 5.7%, while mean body-weight loss was 15.5% at 48 weeks with no evidence of a plateau. In patients with poor baseline glycemic control above 8.5%, the 24 mg dose led to an HbA1c reduction of 4.13% at 48 weeks, and the drug was generally well tolerated with discontinuations due to adverse events of 2.0% in the enicepatide groups versus 0% for placebo. Roche is advancing two ongoing phase III studies in chronic weight management, ENITH-1 and ENITH-2, and plans to initiate a phase III glycemic-control program and cardiovascular outcomes trials in the first half of 2027. Separately, Roche announced that the European Commission has approved Susvimo, a ranibizumab 100 mg/mL solution for injection, for the treatment of neovascular age-related macular degeneration, making it the first and only continuous-delivery treatment approved for nAMD in Europe.

Nektar Therapeutics shares sank 11% as a jury deliberated in its patent dispute with Eli Lilly over its Rezpeg drug. The jury in San Francisco federal court has been deliberating since Friday, and the trial started earlier this month. Court observers told Seeking Alpha on Tuesday that the stock may have dropped after the jury asked about low and no damage results in the dispute.